The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of dovitinib in first-line metastatic or nonresectable primary adrenocortical carcinoma (ACC): SOGUG study 2011-03.
Paula Jimenez
No relevant relationships to disclose
Marta Guix
No relevant relationships to disclose
Nuria Lainez Milagro
No relevant relationships to disclose
Luis Leon Mateos
No relevant relationships to disclose
Maria Jose Mendez Vidal
No relevant relationships to disclose
Miguel Angel Climent Duran
No relevant relationships to disclose
Jesus Garcia-Donas
Honoraria - Novartis
Research Funding - Novartis